Harald Reinhart - 01 Apr 2022 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
01 Apr 2022
Net transactions value
-$79,787
Form type
4
Filing time
17 Nov 2022, 20:37:33 UTC
Previous filing
30 Dec 2021
Next filing
27 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Tax liability $11,186 -246 -0.98% $45.47 24,861 01 Apr 2022 Direct F1, F2
transaction ZLAB American Depositary Shares Options Exercise $5,562 +1,854 +7.5% $3.00* 26,715 15 Nov 2022 Direct F3
transaction ZLAB American Depositary Shares Sale $70,160 -1,754 -6.6% $40.00 24,961 15 Nov 2022 Direct F3
transaction ZLAB American Depositary Shares Sale $4,003 -100 -0.4% $40.03 24,861 15 Nov 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Options Exercise $0 -1,854 -14% $0.000000 11,480 15 Nov 2022 American Depositary Shares 1,854 $3.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer.
F2 The shares were disposed of through a netting transaction to the issuer to cover taxes due. Due to an inadvertent administrative error, the disposition of such shares to cover taxes was not reported on the original Form 4.
F3 The reported transaction was effected pursuant to a sale plan adopted by the Reporting Person, dated 8/23/2022, expires 6/30/2023 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases